ZFPM2 Promoter Methylation in Pre-operative Blood Samples Is Associated with Post-Operative Atrial Fibrillation After Cardiac Surgery by Fischer, Matthew Adam
UCLA
UCLA Electronic Theses and Dissertations
Title
ZFPM2 Promoter Methylation in Pre-operative Blood Samples Is Associated with Post-
Operative Atrial Fibrillation After Cardiac Surgery
Permalink
https://escholarship.org/uc/item/14k0b3kt
Author
Fischer, Matthew Adam
Publication Date
2017
 
Peer reviewed|Thesis/dissertation
eScholarship.org Powered by the California Digital Library
University of California
		
UNIVERSITY OF CALIFORNIA  
Los Angeles 
 
 
 
 
ZFPM2 Promoter Methylation in Pre-operative Blood Samples  
Is Associated with Post-Operative Atrial Fibrillation After Cardiac Surgery 
 
 
 
 
A thesis submitted in partial satisfaction of the 
requirements for the degree Master of Science 
in Clinical Research 
 
 
by 
 
 
Matthew Adam Fischer 
 
 
2017  
		
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Copyright by 
Matthew Adam Fischer 
2017
		ii	
ABSTRACT OF THE THESIS 
 
ZFPM2 Promoter Methylation in Pre-operative Blood Samples  
Is Associated with Post-Operative Atrial Fibrillation After Cardiac Surgery 
 
by 
 
Matthew Adam Fischer 
Master of Science in Clinical Research 
University of California, Los Angeles, 2017 
Professor Janet S Sinsheimer, Chair 
 
 
 Post-operative atrial fibrillation (POAF) is a common cause of morbidity and mortality 
after cardiac surgery. Although clinical risk factors exist, their accuracy is insufficient for 
widespread clinical use. We enrolled 98 adult patients scheduled for cardiac surgery. Clinical 
risk factors for POAF were assessed from a history and physical. Occurrence of POAF was 
observed prior to discharge. DNA methylation data were obtained from whole blood prior to 
surgery. Statistical significance of POAF was analyzed for every CpG after controlling for 
smoking, sex, ethnicity and cell type composition with ReFACTor and CEllFi.  Four CpGs met 
genome wide significance for association with POAF after accounting for covariates and cell 
type composition with both ReFACTor and CEllFi. Two of these CpGs are within the promotor of 
ZFPM2. Further investigation is needed to validate this finding in a separate validation cohort 
and to elucidate the mechanism of ZFPM2 and its involvement in atrial arrhythmias. 
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I.  INTRODUCTION 
 Post-operative atrial fibrillation (POAF) is a common and significant cause of morbidity 
and mortality after cardiac surgery. The incidence of POAF after coronary artery bypass grafting 
(CABG) is between 27 and 40%.  Although there have been many improvements in cardiac 
surgery over the past 20 years, the incidence of POAF has remained relatively constant. 
Alarmingly POAF is also associated with devastating complications such as acute renal failure, 
stroke and congestive heart failure as well as increased hospital resource utilization1. Although 
many clinical risk factors for POAF are known, predictive models of this common perioperative 
complication have thus far been inadequate for widespread clinical use.  
 Given the limited prediction of clinical risk factors, we hypothesize that susceptibility to 
POAF is regulated by genetic and epigenetic risk factors. Kolek et al. investigated several single 
nucleotide polymorphisms (SNPs) to improve prediction of POAF after CABG but their addition 
did not improve the accuracy of clinical risk factor models2. In the study of epigenomics, DNA 
methylation has emerged as an important regulator of disease due to its integration of genetic 
and environmental factors. However, the ability of epigenomic marks to serve as biomarkers for 
perioperative complications is unknown. Given that several studies have correlated 
cardiovascular disease with differences in DNA methylation3,4, we hypothesize that a 
combination of clinical risk factors and differential DNA methylation reflect individual 
susceptibility to POAF. 
 Epigenomics is the study of the effects of chromatin modification on gene expression 
and ultimately phenotype5,6. In this study, we focus on DNA methylation, a subset of 
epigenomics, at cytosine nucleotides contiguous with guanine (CpG). Differences in DNA 
methylation alter the function of DNA and can be associated with changes in gene expression 
and regulation. Each individual’s epigenome changes with age and these differences in DNA 
methylation have been shown to correlate with disease incidence and progression. Epigenomic 
studies have revealed altered DNA methylation in human cardiomyopathy7,8 and mouse studies 
		2	
indicate that DNA methylation can be predictive of susceptibility to cardiac pathology prior to 
environmental stress4. This study seeks to identify DNA methylation sites that are associated 
with POAF and identify differentially methylated loci to aid in its prediction.  
II. METHODS 
 This research was performed as a prospective cohort study because of the dynamic 
nature of DNA methylation.  Patients are enrolled in this IRB approved study pre-operatively 
after informed consent. A detailed history and physical is performed before surgery that 
prospectively records known clinical risk factors for POAF such as age, proposed valve surgery 
and history of paroxysmal atrial fibrillation.    
 The primary outcome in this study is POAF, which is defined as any occurrence of atrial 
fibrillation observed on EKG for at least 30 seconds from the completion of surgery until the 
patient is discharged from the hospital. Patients in the cardiac ICU have continuous 
electrocardiogram monitoring to aid in the electronic and clinical diagnosis of atrial arrhythmias. 
To ensure data validity, the occurrence of POAF is cross-checked with the Society of Thoracic 
Surgeon (STS) database, which includes outcome data including occurrence of POAF recorded 
by the surgical team prior to discharge. 
 The primary predictor of POAF in this study is DNA methylation. For each patient, whole 
blood samples (approximately 6 ml) are collected from an arterial line after induction of 
anesthesia but prior to surgical incision. DNA is extracted from the whole blood samples and 
analyzed by reduced representative bisulfite sequencing (RRBS) which provides single-base 
resolution of DNA methylation. Analysis was restricted to CpGs for which there were at least 10 
reads in an individual patient. CpGs for patients who did not have at least 10 reads were 
considered missing data. Whole blood was chosen for DNA methylation analysis because it is 
easy and safe to collect for assessment of perioperative risk prior to surgery. 
 The clinical covariates included in this study are age, history of paroxysmal atrial 
fibrillation, proposed valve surgery, proposed MAZE procedure, proposed pulmonary vein 
		3	
isolation and post-operative prophylactic amiodarone. These covariates were chosen because 
they are all known clinical risk factors for POAF based on previous studies1,8 or are related to 
the prevention of POAF.  Methylation covariates included in this study are cell type composition, 
smoking status, sex and ethnicity. All of these covariates except cell type composition are 
obtained prospectively from a history and physical prior to surgery.   
 Correcting for cell type composition was performed via two separate methods and their 
results were compared to reduce confounding.  The ReFACTor algorithm9 was used to calculate 
surrogate estimates (ReFACTor components) of the 6 major cell type components of whole 
blood in an unsupervised manner using CpGs that are present in at least 80% of samples. The 
beta value (percent methylation) for each CpG was calculated using the RRBS methylated and 
unmethylated count data.  Next, Pearson correlation of each ReFACTor components with every 
CpG was determined. CpGs that had less than 0.2 correlation with all ReFACTor components 
were determined to have low cell type association and their count data were later analyzed for 
association with POAF.   
 Cell type composition was also calculated using CEllFi10, a tool developed by the 
Pelligrini lab at UCLA, that estimates cell type composition in whole blood using methylation 
sites highly associated with cell type as determined from FACS.  Cell type estimates were 
calculated using CEllFi from the beta values of CpGs present in all samples. These cell type 
estimates were later used as covariates in modeling differential methylation related to POAF. 
  The ReFACTor components were used to exclude CpGs associated with cell type 
composition rather than used as covariates in modeling differential methylation because the 
statistical significance of individual CpGs were assessed with a count based model. This count-
based model is necessary to account for the differences in read count between different 
samples that occur in RRBS.  ReFACTor components are established using PCA on a 
correlation matrix of beta values from a subset of CpGs and, although highly associated with 
cell type, are not a measurable phenomenon directly related to methylation counts.  The cell 
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type estimates from CEllFi, however, are analogous to cell composition percentages obtained 
from FACS and therefore were used as covariates in the count based model to assess for 
differential methylation. 
 Statistical significance of CpGs with POAF was determined using DSS general11 in R. 
This package models the methylation count data with a beta binomial distribution and 
incorporates differences in depth of coverage between CpGs.  First, every CpG was filtered for 
prevalence of at least 50% in all patients. For the cell type correction with ReFACTor, differential 
methylation at CpGs with low ReFACTor correlation (Pearson correlation less than 0.2) was 
modeled after correcting for sex, smoking, ethnicity, age, history of paroxysmal atrial fibrillation, 
valve surgery, MAZE procedure, pulmonary vein isolation, and prophylactic amiodarone.  For 
the analysis with cell type correction with CEllFi, differential methylation was modeled at each 
CpG after correcting for sex, smoking, ethnicity, age, history of paroxysmal atrial fibrillation, 
valve surgery, MAZE procedure, pulmonary vein isolation, prophylactic amiodarone and the 
percent composition of the six most common whole blood cell types. Manhattan and Q—Q plots 
were generated with the QQman package in R.  
 Simple predictive models were constructed with forward and backward stepwise multiple 
logistic regression separately with minimum BIC and AIC using JMP. Results for each model 
were assessed using 5-fold cross validation repeated 10 times using the caret package in R.  
III. RESULTS 
 Ninety-eight patients were prospectively enrolled in this study and nine patients in total 
were excluded leaving eighty-nine patients for analysis.  Six patients were excluded due to 
complete heart block post-operatively requiring permanent pacemaker placement. Two patients 
were excluded for not requiring cardiopulmonary bypass. One patient was excluded because 
they died on post-operative day 2. Among the eighty-nine patients analyzed, thirty-eight 
experienced POAF for an incidence of 42.7% percent. 
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 Clinical covariates are shown in table 1. Manhattan plots using ReFACTor (Figure 1) and 
CEllFi (Figure 3) to account for cell type composition demonstrate association of CpGs with 
POAF. Q-Q plots showing reasonable control of statistical inflation (Figures 2 and 4). The list of 
CpGs meeting genome-wide significance (p value less than 5 x 10-8) are listed in tables 2 and 3 
for ReFACTor and CEllFi cell type composition correction, respectively.  CpGs chr4_38664639, 
ch8_105670444, ch8_105670450 and chr21_45785189 met genome-wide statistical 
significance with both CEllFi and ReFACTor cell type composition correction. Ch8_105670444 
and Ch8_105670450 are within 6 basepairs of each other in the promotor region of Zinc Finger 
Protein, FOG Family Member 2 (ZFPM2).  
 Summary statistics for the POAF prediction models can be found in tables 4 and 5.  The 
AUC, sensitivity and specificity of the predictive model using age, history of paroxysmal atrial 
fibrillation were 0.77, 0.82 and 0.65, respectively.  The AUC, sensitivity and specificity of the 
predictive model using age, history of paroxysmal atrial fibrillation were 0.77, 0.78 and 0.62, 
respectively. 
 Increased methylation at Ch8_105670444 and Ch8_105670450 in the promoter region 
of ZFPM2 is associated with increased risk of POAF. Average methylation at Ch8_105670444 
and Ch8_105670450 for patients who experience POAF are 74.6% and 80% respectively 
(Table 6). Average methylation at Ch8_105670444 and Ch8_105670450 for patients who do not 
experience POAF are 60.4% and 65.8% respectively.  Histograms for the distribution of percent 
methylation of Ch8_105670444 and Ch8_105670450 in patients who experience POAF versus 
those who do not can be found in supplementary figures 1 and 2. 
IV. DISCUSSION 
 This research implicates promoter methylation of ZFPM2 as a risk factor for post-
operative atrial fibrillation. Interestingly, ZFPM2 is expressed in the heart but not in bone 
marrow. These methylation sites discovered in whole blood may reflect cell type non-specific 
changes in methylation associated with gene expression in the heart. ZFPM2 promoter 
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methylation has recently been associated with Tetralogy of Fallot12 though there were no 
patients in this study with Tetralogy of Fallot (TOF) or any other significant congenital heart 
disease.  Patients with Tetralogy of Fallot had a mean methylation of 80.32% compared to 
controls with 59.6% methylation12. Our results show that patients who experience POAF have 
75% and 80% methylation at the studied loci and 60% and 65% methylation in the patients who 
do not experience POAF. ZFPM2 promoter methylation could reflect myocardial stress or high 
intracardiac filling pressures that would be present in both patients with TOF and patients who 
experience post-operative atrial fibrillation. The role of ZFPM2 in atrial arrhythmias is unknown 
and it is also unknown whether ZFPM2 plays a direct role in atrial fibrillation or is a related risk 
factor. ZFPM2 methylation is not associated with known clinical risk factors for POAF. Further 
studies will have to elucidate the mechanism of ZFPM2 related to cardiac arrhythmias. In 
addition, these findings should be confirmed in a separate validation cohort. 
 This result suggests genomic risk factors for post-operative complications that can be 
assessed before surgery.  Importantly, DNA methylation samples of whole blood are easy to 
obtain and confer low risk to the patient.  This methodology can be further analyzed to predict 
other perioperative complications. Prior to surgery patients could obtain whole blood DNA 
methylation risk for post-operative complications along with their other standard pre-operative 
labs. For example, patients with low traditional surgical risk who have methylation biomarkers 
high risk for POAF, could be referred for transcatheter aortic valve replacement (TAVR) instead 
of open aortic valve replacement (AVR) to minimize the risk of POAF given the risk of POAF is 
lower after TAVR13. In addition, the increased cost of TAVR over AVR may be somewhat offset 
by the increased length of stay seen in patients who experience POAF after AVR. The care for 
each patient could be personalized to that patients individual risks and care could be altered to 
minimize adverse events.  
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Supplementary Figure 1: Histogram showing distribution of percent methylation among 
patients who do not experience POAF (above) and patients who do experience POAF 
(below). 
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Supplementary Figure 2: Histogram showing distribution of percent methylation among 
patients who do not experience POAF (above) and patients who do experience POAF 
(below). 
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